Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07725601

VNS Algorithm for Advanced Dosing

The goal of this clinical trial is to compare the standard programming of the VNS device (Control) to a modified programming (Augusta Way) in adults with epilepsy. The main question it aims to answer is:

Does the modified programming of the VNS reduce seizures faster than the standard programming?

Participants in both groups will:

1. Attend up to 3 study visits every 3 months for 2 years 2. Answer questionnaires to assess quality of life and cognitive function 3. Maintain a diary of seizure activity

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Wellstar MCG Hospital

Augusta, Georgia, 30912, United States

Location status: Recruiting

Location contact

Brandy Quarles, MPH

CONTACT

[email protected]

7067210390

About this study

Little has changed in the last 10 years or more in regard to Vagus nerve stimulator (VNS) therapy programming parameters despite new technological advances. The goal of our study is to provide a comprehensive VNS dosing protocol which VNS programmers can refer to as the standard care of treatment escalation in patients with drug refectory epilepsy. Given the lack of newly published data regarding VNS system parameters, this study will allow epileptologists, general neurologists and neurosurgeons alike, access to an updated reference and model of VNS parameter escalation and treatment.

The investigators at Augusta University have developed a programming paradigm that appears to provide good clinical outcomes for VNS patients. The study will provide a comprehensive assessment of an experimental group ("the Augusta Way") programmed with a modified, more rapid titration paradigm developed at our site vs. "best clinical practice" (standard titration paradigm) control group of patients with VNS devices. The patients will be followed for at least 24 months post implantation. The study will assess safety of the new programming paradigm and will assess efficacy based upon seizure outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who are clinically determined to be candidates for VNS implantation for seizure control
  • Subject/legally authorized representative able to provide informed consent.

Exclusion criteria

  • Subjects with VNS system treating pathologies other than drug refractory epilepsy or medical co-morbidities that prevent any surgical intervention

Treatment and study plan

Rapid Titration VNS programming

Device

Modified programming of VNS that provides rapid titration

Standard VNS programming

Device

Standard of Care VNS programming

Primary outcomes

  1. Seizure Diary

    Time frame: From enrollment to end of participation at 2 years

    A seizure diary is a personalized log used to record seizure activity, medication adherence, and potential triggers

Study contacts

Contact information is provided by the study sponsor or research team.

Brandy Quarles, MPH

CONTACT

[email protected]

706-721-0390

Sponsors and collaborators

Lead sponsor

Fernando Vale

Other

Collaborators

  • Augusta University

Registry information

Official study title

VNS Algorithm for Advanced Dosing: Example Guided Mode Titrations "The Augusta Way"

Important dates

Study start
2025
Primary completion
2028
Study completion
2030
First posted
Jul 24, 2026
Registry last updated
Jul 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.